Lonvo‑z trial update — 62% of treated patients attack‑free at 6 months

Hereditary angioedema is a swelling disease that can send people to the ER, shut down daily life, and force them onto chronic preventive drugs. The obvious dream has been a one-time treatment that turns the disease down at its source. That has been mostly theoretical in gene editing — especially inside the body, where delivery and safety are the hard parts. What changed this week is that Intellia Therapeutics posted Phase 3 results showing its one-time CRISPR-based therapy, lonvoguran ziclumeran, or lonvo-z, worked in hereditary angioedema. ### What is lonvo-z actually trying to do? Lonvo-z is built to knock down the KLKB1 gene in the liver. That matters because KLKB1 helps make plasma kallikrein, and plasma kallikrein drives bradykinin, the molecule that causes the swelling attacks in hereditary angioedema. So the strategy is pretty direct — edit the liver once, lower kallikrein for the long haul, and stop attacks before they start. Not a pill. Not a recurring injection. A single IV infusion. ### Why is hereditary angioedema a good test case? Because the biology is unusually clean. In many diseases, gene editing has to hit the right cells, fix a messy pathway, and still show a clear clinical benefit. Here, the pathway is narrower. Patients also have a very concrete outcome that matters: attacks. You can count them. You can compare them. And you can see whether people still need long-term prophylaxis. ### What did the Phase 3 trial show? The HAELO trial enrolled 80 patients with type I or II hereditary angioedema. Fifty-two got a single 50 mg infusion of lonvo-z. Twenty-eight got placebo. Over the six-month efficacy window, lonvo-z cut the mean monthly attack rate by 87% versus placebo. The monthly rates were 0.26 in the treatment arm and 2.1 in the placebo arm. The headline secondary result — the one people keep quoting — was that 62% of treated patients were both attack-free and off long-term prophylaxis through six months, versus 11% on placebo. ### Why is the 62% figure getting so much attention? Because it is easier to understand than an average attack-rate reduction. “Attack-free and therapy-free” is the real-world version of success. Basically, this is the difference between “the disease got quieter” and “for six months, many patients had no attacks and needed no chronic preventive therapy.” For a disease managed with expensive ongoing drugs, that is a big deal. ### Is this really a CRISPR first? In one important sense, yes. Intellia framed this as the first Phase 3 success for an in vivo CRISPR gene-editing therapy — meaning the editing machinery is delivered directly into the patient, rather than cells being edited outside the body and reinfused later. That does not mean every scientific risk is gone. But it does mean the field now has late-stage evidence that in-body editing can produce a clear clinical win in a defined disease. ### What about safety? So far, the profile looks encouraging. Intellia said adverse events were mostly mild or moderate and transient, with no treatment-related serious adverse events reported in the lonvo-z arm. But the catch is that gene editing is judged over long timelines. Six-month efficacy and a clean topline readout are strong. They are not the same thing as years of post-approval comfort. ### What happens next? Intellia has already started a rolling U.S. biologics license application. The company said it expects to complete the filing in the second half of 2026. If approval follows, lonvo-z could become a real test of whether payers will fund a one-time gene-editing therapy up front in exchange for potentially years of avoided chronic treatment costs. ### Bottom line The news is not just that lonvo-z worked. It is that a one-time, in-body CRISPR treatment produced late-stage data strong enough to look commercially and clinically real. The remaining questions are the practical ones — how durable the benefit stays, how regulators weigh long-term follow-up, and whether insurers will pay for the one-shot version of a disease now managed as a subscription.